Highlander Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Highlander Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-42	Closed	–	–	628
2020 Q4	$0	Hold	42	–	–	﹤0.01%	619
2020 Q3	$0	Buy	+42	New	+$75	﹤0.01%	614
2020 Q2	–	Sell	-42	Closed	–	–	622
2020 Q1	$0	Buy	+42	New	+$125	﹤0.01%	645
2019 Q3	–	Sell	-42	Closed	–	–	676
2019 Q2	$0	Hold	42	–	–	﹤0.01%	701
2019 Q1	$0	Buy	+42	New	+$255	﹤0.01%	711
2018 Q4	–	Sell	-42	Closed	–	–	718
2018 Q3	$0	Hold	42	–	–	﹤0.01%	747
2018 Q2	$1K	Buy	+42	New	+$430	﹤0.01%	735
2018 Q1	–	Sell	-42	Closed	–	–	774
2017 Q4	$0	Hold	42	–	–	﹤0.01%	750
2017 Q3	$1K	Hold	42	–	–	﹤0.01%	727
2017 Q2	$1K	Hold	42	–	–	﹤0.01%	735
2017 Q1	$1K	Hold	42	–	–	﹤0.01%	748
2016 Q4	$1K	Hold	42	–	–	﹤0.01%	749
2016 Q3	$1K	Hold	42	–	–	﹤0.01%	755
2016 Q2	$1K	Hold	42	–	–	﹤0.01%	762
2016 Q1	$1K	Hold	42	–	–	﹤0.01%	776
2015 Q4	$1K	Hold	42	–	–	﹤0.01%	816
2015 Q3	$0	Hold	42	–	–	﹤0.01%	846
2015 Q2	$0	Buy	+42	New	+$308	﹤0.01%	854
2015 Q1	–	Sell	-43	Closed	–	–	851
2014 Q4	$0	Hold	43	–	–	﹤0.01%	861
2014 Q3	$423	Hold	43	–	–	﹤0.01%	831
2014 Q2	$483	Hold	43	–	–	﹤0.01%	801
2014 Q1	$519	Hold	43	–	–	﹤0.01%	819
2013 Q4	$540	Hold	43	–	–	﹤0.01%	811
2013 Q3	$714	Hold	43	–	–	﹤0.01%	812
2013 Q2	$651	Buy	+43	New	+$653	﹤0.01%	794

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Highlander Capital Management's LXRX Position: Q1 2021 in Review

Highlander Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2021, closing a stake of 42 shares.

Highlander Capital Management first reported a position in LXRX in Q2 2013 and held it in 25 quarters. The position peaked at $1K in Q2 2018. 107 funds tracked by Wall St. Rank hold LXRX as of Q1 2021.

Highlander Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Highlander Capital Management sold 42 Lexicon Pharmaceuticals shares in Q1 2021.
Highlander Capital Management first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 25 quarters.
Highlander Capital Management's Lexicon Pharmaceuticals position peaked at $1K in Q2 2018.
107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2021.

Based on Highlander Capital Management's 13F filing for Q1 2021, filed 14 May 2021.